/Investor DB

Ikarian Capital

Venture capital

Dallas · Series A–Late Stage

Also known as IKARIAN CAPITAL, LLC

Find your way into Ikarian Capital

Sign up to see every warm intro you have to Ikarian Capital

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Ikarian Capital team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

✨ Fox Verdict
Sign up to see your fit

Investment thesis

Ikarian Capital invests in biotech companies advancing drug discovery and development, led by a team with scientific and biotech-specific finance expertise. It selects companies pursuing cutting-edge science with sound business fundamentals across the spectrum of early- to late-stage clinical trials, remaining agnostic to indication, market cap, and geography. The firm deploys transformational, long-term capital to support emerging companies as they progress through the clinic. It emphasizes a selective, contrarian approach backed by a proprietary process aligned with the team's core expertise, and is committed to building an enduring business with strong values and high ethical standards.

Source: firm website, verified Oct 13, 2026.

Stage
Series A–Late Stage
HQ
Dallas, US
Instruments
Equity
Last 12 months
2 investments
AUM
$698M
Tracked investments
4
IPOs
1

What they invest in

from 3 of 4 portfolio companies

Biotech ×2Healthtech ×2Enterprise Software ×1Fintech ×1PropTech ×1

HQs:United States×3New Zealand×1

Investments · 4 tracked

founders shown can be your intro path

By year:2026 · 22021 · 13 dated

Jasper Therapeuticsjaspertherapeutics.cominNASDAQ: JSPRJul 2026

Jasper Therapeutics develops briquilimab, a targeted anti-KIT monoclonal antibody designed to deplete mast cells for treating chronic immunological and inflammatory diseases.

BiotechHealthtechRedwood City, US

Judith Shizuru(Director)Herb Cross(Executive Officer)inJeet Mahal(Executive Officer, Director)inPatrick Crutcher(Director)Svetlana Lucas(Director)Wenru Song(Executive Officer)

Co-investorsAvego BioScience CapitalQiming Venture Partners USATSVCAbingworth

Jasperjasper.ioin𝕏

Jasper is a commercial real estate fund management firm that deploys and manages capital for institutional investors into industrial, logistics, and other asset classes across Australia and New Zealand.

Enterprise SoftwareFintechPropTechAuckland, NZ

Mark Campbell(CEO and Executive Director)in

Co-investorsBlackstoneArc AngelsFantail VenturesIcehouse VenturesBessemer Venture PartnersCoatue Management+5 more

Kira Pharmaceuticalskirapharma.cominAug 2026

Kira Pharmaceuticals is a biotech company developing therapies targeting complement biology to treat complement-mediated diseases.

BiotechHealthtechCambridge, US

Wenru Song(Founder)in

Co-investorsForesite CapitalQuan CapitalVivo Capital

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

ValenzaBio

Exits · 1

1 IPOs

Jasper TherapeuticsNASDAQ: JSPR

Portfolio news

latest coverage across their companies

Frequently asked questions

What stage does Ikarian Capital invest at?
Ikarian Capital invests at the Series A, Series B, Series C, Growth, Late Stage stages.
What sectors does Ikarian Capital focus on?
Ikarian Capital focuses on Biotech.
Where is Ikarian Capital located?
Ikarian Capital is headquartered in Dallas, US.

Similar investors

Featured in lists